top of page
All Posts


Europe’s moment: We could be the heroes of biotech
Capital is tight, and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures. recent delivery by Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners * "Even in uncertain times, life sciences remain at the core of what our societies need most. Large pharmaceutical companies depend on a steady flow of breakthrough ideas from biotechs, and that need keeps our ecosystem mo
Georges HAZAN
Feb 152 min read


BROTHERS & Partners 2025 Investment Trends
' Looking Back & Forward '' Market landscape VC and M&A activity have declined in both total deal count and value over the past three years, while partnerships show fewer deals but higher total deal value. This shift represents a significant change in the investment landscape, as members at BROTHERS & Partners have identified the following investment trends: - Investment trends : Late-stage deals take the spotlight. Rare diseases, next-gen modalities, and AI/ ML lead the
Georges HAZAN
Dec 22, 20253 min read


Melatonin: a promising new approach in Alzheimer’s treatment
Neurodegeneration Melatonin shows promise in Alzheimer's treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study. A groundbreaking study conducted by researchers at Nanjing Pharmaceutical University has introduced an innovative therapeutic strategy for combating Alzheimer's disease , linking aging processes with neurodegenerative diseases. The researchers employed an AI-driven screening method
Georges HAZAN
Nov 25, 20253 min read


An Interview with Carl Gordon, Managing Partner, OrbiMed Advisors
OrbiMed is a global healthcare investment firm that finances companies across all stages of the life sciences sector, from early-stage biotechs to large pharmaceutical enterprises. How would you describe the current investment climate for the biotech sector? Do you believe the difficult period the industry has faced in recent years is finally coming to an end? I think it’s an exciting time for the sector. It’s never easy to be a biotech investor, but over the last several mon
Georges HAZAN
Nov 23, 20255 min read


European Family CIOs Rethink U.S. Exposure Amid Volatility
The geopolitical landscape is the key challenge that they face in their investment decision-making. The CIOs of British and mainland...
Georges HAZAN
Jul 15, 20253 min read


Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem
Paris is known for many things, from romance to art to world-beating croissants. But perhaps one of its lesser-known attributes is that...
Georges HAZAN
Jul 1, 20256 min read
Georges HAZAN
Jun 24, 20250 min read
Deluge of VC capital for European life sciences to kick off the year
PitchBook - European life sciences kicks off year with deluge of VC capital
Georges HAZAN
Mar 18, 20251 min read
Georges HAZAN
Mar 2, 20250 min read
bottom of page
